{"id":"W2137043950","doi":"10.1016/s1470-2045(15)00006-6","title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":434,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Ottawa","funders":"AstraZeneca; Eli Lilly and Company","keywords":"Afatinib; Erlotinib; Medicine; Clinical endpoint; Internal medicine; Lung cancer; Erlotinib Hydrochloride; Oncology; Population; Randomized controlled trial; Surgery; Cancer; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001807102,0.002680914,0.004671586,0.0004890463,0.0005336893,0.001841977,0.001391932,0.002832984,0.009406119],"category_scores_gemma":[0.002092127,0.000886453,0.004287839,0.0004602956,0.001435429,0.002295659,0.0005452673,0.005324584,0.001882992],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001157637,"about_ca_system_score_gemma":0.001023388,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001297768,"about_ca_topic_score_gemma":0.003116689,"domain_scores_codex":[0.9992419,0.0003441798,0.00004814951,0.0001637515,0.00004753303,0.0001545417],"domain_scores_gemma":[0.9990944,0.0002598149,0.000182455,0.00007812211,0.00006246873,0.0003227743],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9830086,0.002986166,0.0002770238,0.0006087224,0.001040368,0.00004006912,0.00004522492,0.0003827605,0.00119679,0.00009982295,0.0007862083,0.009528244],"study_design_scores_gemma":[0.9689375,0.02922716,0.0005182039,0.00002604131,0.0003372163,0.00003366768,0.00002028755,0.0002791283,0.0001131935,0.0001477926,0.0003453577,0.00001450546],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9795583,0.008396246,0.000806301,0.001490602,0.001477446,0.003311779,0.001707445,0.0002338463,0.003018086],"genre_scores_gemma":[0.9833922,0.003516605,0.001270921,0.001407937,0.0005916456,0.003289349,0.001444992,0.00004142492,0.005045],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009406119,"threshold_uncertainty_score":0.0314666,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06509205628352367,"score_gpt":0.4127227631918144,"score_spread":0.3476307069082907,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}